Concepedia

Author

Björn Eliasson

University of GothenburgORCID

Also Known As

Andrew T Hattersley, Araz Rawshani, B Eliasson, B. ELIASSON, B. Eliasson, B. R. G. Eliasson, BJORN ELIASSON, BJÖRN ELIASSON, Bjorn Eliasson, Björn Eliasson

436

Publications

22K

Citations

73

H-Index

108

Concepts

All Affiliations

University of GothenburgSahlgrenska University HospitalCentre of Registers Vastra GotalandUppsala UniversityLund University
BE

About

Björn Eliasson is an author at University of Gothenburg specializing in medicine, diabetes, and cardiovascular disease.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

34

51

5.1K

2

Public Health

23

30

2.5K

3

Health Sciences

13

13

928

4

Social Sciences

1

1

26

5

Biostatistics

1

1

15

Björn Eliasson

×

214

Publications

19.4K

Citations

69

H-Index

YearCitations

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed,

The Lancet

2018

1.7K

Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Aidin Rawshani, Araz Rawshani, Stefan Franzén,

New England Journal of Medicine

2018

1.3K

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes

Aidin Rawshani, Araz Rawshani, Stefan Franzén,

New England Journal of Medicine

2017

1.3K

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes

Nikolaus Marx, Massimo Federici, Katharina Schütt,

European Heart Journal

2023

1.2K

Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks

Naveed Sattar, Araz Rawshani, Stefan Franzén,

Circulation

2019

538

One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients

Mathijs C. Bunck, Michaëla Diamant, A. H. Corner,

Diabetes Care

2009

385

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study

Peter Ueda, Henrik Svanström, Mads Melbye,

BMJ

2018

352

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Paresh Dandona, Chantal Mathieu, Moshe Phillip,

The Lancet Diabetes & Endocrinology

2017

286

SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe

Lisa Pennells, Stephen Kaptoge, Helena Bleken Østergaard,

European Heart Journal

2023

255

The National Diabetes Register in Sweden

Soffia Guðbjörnsdóttir, Jan Cederholm, Peter M. Nilsson,

Diabetes Care

2003

253

Page 1